After 12 months of testing, Presbia – a medical device company and leader in near vision restoration – has revealed test results regarding its corneal inlay treatment aimed at treating presbyopia, Flexivue Microlens. The results certainly seem to indicate an excellent overall performance and a high success rate for patients tested. All patients showed a significant improvement in near visual acuity from baseline, with 78 percent of those tested no longer requiring reading glasses to see objects up close.

The study was based on a randomized sample of 40 emmetropic patients between the ages of 45 and 60. It was conducted at two European sites, the University of Crete in Greece and Prato Hospital in Italy. Patients achieved dramatic improvements in their near vision from just one week after the procedure, often improving from pre-op vision of 20/100, to 20/25.

Perhaps even more significantly, the study also showed that patients experienced little to no change in their distance visual acuity using both eyes. Distance vision in the operated eye did, however, show declines of about two lines on the Snellen chart. Regardless, all patients went on to record a binocular distance vision of 20/25 or better within one month of the surgery, with continued improvement over time. Patients also reported a “very high satisfaction rate” one year after implantation.

Dr. Michael Gordon, founder of the Gordon Binder Vision Institute in San Diego, CA and a member of Presbia’s Medical Advisory Board has the following to say about the test results: “This study demonstrates that the Flexivue Microlens^® provides a clinically useful and very satisfactory treatment for emmetropic presbyopia.” Prof. Pallikaris, Chairman of Presbia’s Medical Advisory Board noted: “The fact that all respondents either don’t use reading glasses at all, or less than 50 percent of the time, shows that the Flexivue is a superior treatment for this common eye ailment that affects more than one billion people globally.”